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A randomized controlled trial of blood flow and stenosis sur- though the main mode of therapy is currently correction
veillance of hemodialysis grafts. of stenosis by percutaneous transluminal angioplasty
Background. It is widely accepted that hemodialysis graft (PTA) [1–3], the optimum timing of PTA has not yetsurveillance combined with correction of stenosis reduces
been determined. The traditional method has been tothrombosis and prolongs graft survival. Nevertheless, few ran-
domized controlled trials have evaluated this approach. refer for angiography based upon clinical suspicion of
Methods. In this randomized controlled trial, 101 patients stenosis, or to wait until thrombosis to correct stenosis.
were assigned to control, flow (Qa), or stenosis groups, and This approach has fallen into disfavor because it haswere followed for up to 28 months. All patients had monthly Qa
been associated with a high rate of graft thrombosis andmeasured by ultrasound dilution and quarterly percent stenosis
measured by duplex ultrasound. Referral for angiography was failure [1, 2]. This has led to the proposal that surveil-
based on the following criteria: (1) control group (N  34), lance programs be used to detect graft dysfunction or
clinical criteria; (2) flow group (N  32), Qa 600 mL/min stenosis so that PTA can be applied before thrombosisor clinical criteria; and (3) stenosis group (N  35), stenosis
[1–4]. The most widely recommended surveillance method50% or clinical criteria. Stenosis 50% during angiography
was corrected by preemptive percutaneous transluminal angio- has been monthly Qa measurements.
plasty (PTA). The rationale for Qa surveillance depends upon two
Results. The preemptive PTA rate in the control group (0.22/ assumptions. The first is that monthly Qa measurementspatient year) was two thirds the rate in the flow group (0.34/
accurately predict thrombosis. Although this assumptionpatient year), and was highest in the stenosis group (0.65/patient
year, P  0.01). The percentage of grafts that thrombosed seems plausible, we [5, 6] and others [7] have found that
was similar in the control (47%) and flow groups (53%), but Qa is an inaccurate predictor of thrombosis, and this
reduced in the stenosis group (29%, P  0.10). Two-year graft conclusion has been supported by a meta-analysis [8].survival was similar in the control (62%), flow (60%), and
Moreover, reanalysis of two widely cited studies [9, 10]stenosis groups (64%) (P  0.89).
Conclusion. Qa and stenosis surveillance were not associated that have supported Qa surveillance shows their results
with improved graft survival, although thrombosis was reduced are similar to ours [11]. Qa is an inaccurate predictor ofin the stenosis group. The most important factors in this result thrombosis mainly because wide hemodynamic variationmay be that monthly Qa and quarterly stenosis measurements
is present throughout dialysis, and this impairs the repro-were not accurate or timely indicators of risk of thrombosis or
progressive stenosis. This study does not support the concept ducibility of Qa measurements [12, 13]. Failure to accu-
that Qa or stenosis surveillance are superior to aggressive clini- rately predict thrombosis would impair any potential
cal monitoring.
benefit from preemptive intervention.
The second assumption in surveillance is that timely
intervention reduces thrombosis and prolongs graft life.Progressive stenosis of hemodialysis grafts leads to
Most studies that have evaluated surveillance, whetherdecreased blood flow (Qa), stasis, and thrombosis. Al-
by Qa or venous pressure, have used historic control groups,
sequential groups, or have been retrospective [14–23].
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bosis rate because of multiple thromboses in a small The 101 study patients were randomly assigned to
number of grafts [29]. Two studies have evaluated steno- control, flow, or stenosis groups, and were followed until
sis surveillance by duplex ultrasound [30, 31]. In a study graft failure or the end of the study in February 2001.
of new grafts, surgical revision for more than 50% steno- Group assignments were supervised by a single investiga-
sis improved graft survival [30]. In the second study, tor who was not involved in patient care (S.J.R.); no one
preemptive PTA failed to improve graft survival, but else was aware of group assignments. Randomization
that study has been criticized because the surveillance was determined by a random number table that was
group had more prior interventions than the control generated for this study (Systat 5.2 for Macintosh, Rich-
group [31]. In a subset analysis of 21 patients without mond, CA, USA). Blocked randomization was used to
prior interventions, PTA was associated with improved ensure that numbers of subjects in each group were ap-
graft survival [32]. Finally, in a preliminary report, Qa proximately equal [36]. Only one graft/patient was in-
surveillance failed to improve graft survival (abstract; cluded in the study.
Moist et al, J Am Soc Nephrol 12:34A, 2002). However, All patients underwent monthly Qa measurements bythe control group underwent dynamic venous pressure ultrasound dilution and quarterly stenosis measurements
surveillance, which may have obscured any potential by duplex ultrasound. Referral for angiography, how-
benefit from Qa surveillance. ever, was restricted to the following criteria: (1) controlIt is noteworthy that the accuracy of venous pressure
group, clinical criteria alone; (2) flow group, Qa 600in predicting thrombosis is also controversial [33, 34]. In
mL/min or clinical criteria; (3) stenosis group, stenosisaddition, in a preliminary report, a randomized con-
50% or clinical criteria.trolled trial found that static venous pressure surveillance
A single investigator (S.J.R.) was aware of the resultsdid not improve graft survival (abstract; Dember et al,
of Qa and stenosis measurements. Clinical criteria forJ Am Soc Nephrol 13:600A, 2002).
referral were determined by attending nephrologists andThus, despite wide acceptance that surveillance is ben-
were based upon suspicion of graft dysfunction or steno-eficial, the foregoing shows that a benefit has not yet
sis (Table 1). Stenosis was defined as percent reductionbeen established. Clearly, further studies are needed to
in luminal diameter. For all groups, stenosis of50% onevaluate the effectiveness of surveillance in reducing
angiography was corrected by PTA. Thrombosed graftsthrombosis and improving graft survival. The relative
underwent thrombolysis and angiography with correc-benefit of surveillance by Qa vs. stenosis is also unknown.
tion of stenosis by PTA. Grafts with unsuccessful PTAIn this randomized controlled trial, we evaluated whether
were defined as failures and were referred for surgicalintervention based upon Qa or stenosis provide a benefit
when added to intervention based upon clinical criteria revision or abandoned. Revision was considered failure
alone. because the venous anastomosis was abandoned and the
graft was extended proximally up the arm.
METHODS Patient data, measurements, procedures
Patients and protocol
A computer database was maintained for recording
We followed the Consolidated Standards of Reporting diagnoses, demographic information, graft measurements
Trials statement for documenting randomized controlled and events, and serum albumin levels. Albumin levels
trials (Fig. 1) [35]. Patients with polytetrafluoroethylene were measured by autoanalyzer at study entry. Qa was
(PTFE) grafts from two dialysis units (Dialysis Clinic, measured monthly by ultrasound dilution (Transonic Sys-
Inc. and Dialysis Center of Shreveport) were enrolled tems, Inc., Ithaca, NY, USA) [37]. Measurements were
in the study at various times beginning in November taken in duplicate at any time during dialysis except
1998. The study protocol was approved by the Institu- within the first and last 15 minutes. When two measure-tional Review Boards of Louisiana State University and
ments differed by more than 10%, a third measurementthe parent corporations of the dialysis units (Dialysis
was taken. Measurements were then averaged.Clinic, Inc., Nashville, TN, USA; Fresenius Medical Care,
A single qualified technician (J.M.E.) performed quar-Walnut Creek, CA, USA). After obtaining written in-
terly duplex ultrasound studies with a Siemens Sonolineformed consent, patients underwent a Qa measurement
Versa Scanner and a 7.5 or 5.0 MHz linear transducerby ultrasound dilution, and stenosis and Qa measurements
(Siemens Medical Systems, Inc., Issaquah, WA, USA).by duplex ultrasound, in order to establish baseline values.
He was blinded to group assignment and previous ultra-From a total of 128 eligible patients, 101 completed these
sound studies. The graft, arterial and venous anastomo-measurements and were enrolled. Analysis of enrolled
ses, inflow artery, and outflow vein were evaluated inpatients was by “intention-to-treat” (all enrolled patients
sagittal and transverse planes with and without color.were included in the analysis). The remaining 27 patients
Images were recorded on videotape for subsequent anal-were not enrolled because graft failure, transfer, trans-
ysis. Location and percentage of stenosis were recorded.plantation, or infected graft removal occurred before
entry requirements could be met. Flow velocity was measured with the transducer at 60
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Fig. 1. Flow diagram of patient progress
through phases of randomized trial that tested
graft survival by Kaplan-Meier analysis. *Cen-
sored grafts include (1 ) current, grafts that
were still being monitored at the time the
study ended; or (2 ) other end point, grafts
censored because of death, transfer, trans-
plant, recovery of renal function, graft re-
moval due to infection, or graft ligation unre-
lated to stenosis or thrombosis.
Table 1. Reasons for preemptive percutaneous transluminal angioplasty (PTA) in each group
Control group Flow group Stenosis group
Number of preemptive PTAs 7 15 26
Criteria for preemptive PTAa
Prescribed blood pump speed not attained 5 2 —
High dynamic venous pressureb 3 2 —
Excessive bleeding postdialysis 4 — —
Swollen arm 1 1 1
Qa 600 mL/min — 12 —
Stenosis 50% — — 25
Qa is blood flow.
a Some grafts had more than one criterion for preemptive PTA
b Measured at prescribed or actual blood pump speed (if prescribed blood pump speed not attainable)
with respect to the plane of the graft. Qa was computed were analyzed by chi-square test. Kaplan-Meier survival
analysis was used to compare outcomes among the threefrom luminal diameter and time-averaged flow velocity.
groups. The proportional hazards model was used to
Analysis determine whether adjustment for the variables in Ta-
ble 2 influenced outcome. A backward elimination proce-Data are reported as mean SE. Normally distributed
data were analyzed by analysis of variance. Categories dure was used to determine which variables were signifi-
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Table 2. Patient and graft characteristics of the three groups at study entry
Control group Flow group Stenosis group P value
No. of patients 34 32 35
African American race 30 (88%) 32 (100%) 34 (97%) 0.07
Female 21 (62%) 21 (66%) 17 (49%) 0.33
Diabetes mellitus 19 (56%) 12 (38%) 17 (49%) 0.32
Patient age years 532a 553 593 0.28
Serum albumin g/dL 3.90.1 4.00.8 3.80.1 0.38
Graft age days 27676 502135 41485 0.29
Median graft age days 94 225 196 0.20
Range of graft ages days 21–2355 45–2918 24–2099
No. of prior PTAs 1.10.3 0.80.2 0.80.2 0.64
Grafts without prior procedures 22 (65%) 19 (59%) 26 (74%) 0.42
Loop configuration of graft 15 (44%) 14 (44%) 14 (40%) 0.93
Qa (mL/min), by ultrasound dilution 1333123 1219114 1253106 0.77
Qa (mL/min), by duplex ultrasound 110299 1147101 98576 0.44
Percent stenosis 353 374 354 0.94
Qa is blood flow.
a Mean  SE
Table 3. Comparison of graft events in the three groups
Control group Flow group Stenosis group P value
Preemptive PTA rate number/patient year 0.22 0.34 0.65b
Thrombosis rate number/patient year 0.68 0.91a 0.50
Percentage of grafts that thrombosed during study 47.1% 53.1% 28.6% 0.10
Kaplan-Meier survival analysis
Probability grafts were thrombosis-free at 1 year 0.45 0.52 0.70 0.12
Probability grafts were event-freec at 1 year 0.34 0.47 0.36 0.55
Probability grafts survived 2 years 0.62 0.60 0.64 0.89
a P  0.02; b P  0.01 comparison vs. control group
c Event-free denotes no thrombosis or preemptive percutaneous transluminal angioplasty (PTA)
cant. A Z statistic was used to compare rates (events/ were for group-specific criteria (Qa 600 mL/min or ste-
patient year). Significance was set at P  0.05, and P nosis50%, respectively). Group-specific criteria domi-
values were two-tailed. nated in these groups because these criteria tend to occur
earlier than clinical criteria.
The high rate of preemptive PTA in the stenosis groupRESULTS
was associated with reduced thrombosis (Table 3). The
Characteristics of control, flow, and stenosis groups
thrombosis rate was highest in the flow group, but this
Table 2 compares patient and graft characteristics of is misleading in that it was caused by multiple thrombo-
the three groups at study entry. There were no statisti- ses in three grafts. In contrast, when the percentage of
cally significant differences between the groups. Most grafts that thrombosed at least once was compared, the
patients were African Americans, although the percent- control and flow groups were similar, and the stenosis
age in the control group was slightly less than in the group remained lower.
other two groups. Mean graft age was lowest in the
Kaplan-Meier analysis shows there was a trend toward
control group, but this difference was not significant.
delayed first thrombosis after study entry in the stenosisThe three groups had similar mean Qas, stenoses, and group (P  0.12) (Table 3, Fig. 2). We used the propor-numbers of prior procedures.
tional hazards model to determine whether adjustment
for the variables in Table 2 altered this result. The onlyPreemptive PTA and thrombosis
significant variable in the multivariable model was QaOverall PTA and thrombosis rates were substantial,
by duplex ultrasound at study entry (P  0.008), andindicating progressive stenosis characterized the grafts
inclusion of this variable strengthened the trend of de-in this study (Table 3). The preemptive PTA rate in the
layed thrombosis in the stenosis group (P  0.05). It iscontrol group was two thirds the rate in the flow group,
notable that graft age, number of prior PTAs, whetherand was highest in the stenosis group. Several clinical
a graft had prior procedures, and Qa by ultrasound dilu-criteria led to referral for PTA in the control group
(Table 1). In the flow and stenosis groups, most PTAs tion at study entry were not significant. Figure 3 shows
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Fig. 2. Kaplan-Meier comparison of thrombosis-free graft survival in
the three groups (P  0.12). Circles indicate thrombosis (stepdowns) Fig. 4. Last monthly blood flow (Qa) values before thrombosis in con-or censoring (horizontal portions). trol (N  18), flow (N  31), and stenosis (N  11) groups (P  0.77).
Because of repeated thrombosis in some grafts, Qa was not available
before all thromboses. Solid circles indicate mean  SE. Dashed line
indicates Qa  600 mL/min.
sis. The figure also shows that four thrombosed grafts
in the flow group met criteria for angiography before
thrombosis. Three thrombosed before angiography
could be scheduled and one patient missed his appoint-
ment. These thromboses did not appear to affect graft
survival because three had successful PTAs postthrom-
bosis, and the fourth was already unsalvageable in that
a recent preemptive PTA had yielded a minimal im-
provement in Qa.
Graft survival
Kaplan-Meier analysis was used to determine whether
surveillance improved graft survival, with failure defined
as graft abandonment or surgical revision. There were
no significant differences in survival during follow-up
periods of up to 28 months (P  0.89) (Table 3, Fig. 5).Fig. 3. Kaplan-Meier comparison of event-free graft survival in the
In the proportional hazards model, once again the onlythree groups (P 0.55). Circles indicate events (thrombosis or preemp-
tive percutaneous transluminal angioplasty (PTA) at stepdowns) or significant variable was Qa by duplex ultrasound (P 
censoring (horizontal portions). 0.001), and it did not change the conclusion that survival
was similar in the three groups (P  0.45). Only one
graft in each group underwent revision; in each case a
jump graft bypassed the venous anastomosis. Redefiningthat time to first event (thrombosis or preemptive PTA)
graft failure solely as abandonment (but not revision)was similar in the three groups (P  0.55).
did not alter the proportional hazards result (P  0.32).In order to understand why Qa surveillance failed to
reduce thrombosis, we examined the last monthly Qas
Confidence intervals (CIs) and significancebefore thrombosis in all three groups. Figure 4 shows
Because many of the differences in Table 3 were notthat the last Qa was generally well above the 600 mL/
significant, we computed 95% confidence intervals (CIs)min threshold that was used to refer for PTA in the flow
group. Thus, Qa was an inaccurate predictor of thrombo- for differences between flow or stenosis group vs. control
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Fig. 5. Kaplan-Meier comparison of cumulative graft survival in the
three groups (P  0.89). Circles indicate graft failure (stepdowns) or
censoring (horizontal portions).
Fig. 6. 95% CIs for differences between flow or stenosis group and
control group. The following variables were analyzed. (A ) Proportion
of grafts that thrombosed during study. (B ) Kaplan-Meier probability
that grafts remained thrombosis-free 1 year after study entry. (C )group (Fig. 6). We considered the proportion of grafts
Kaplan-Meier probability that grafts survived for 2 years after study
that thrombosed during the study, and the probabilities entry. For example, probability of graft survival in the stenosis group
minus survival in the control group may have been as low as 0.25 orthat grafts remained thrombosis-free at 1 year or survived
as high as 0.27. CIs that exclude zero would indicate differencesfor 2 years after study entry. For thrombosis (Fig. 6 A
between groups were significant.
and B), differences between the stenosis and control
groups were nearly significant (CIs nearly excluded 0).
These CIs suggest stenosis surveillance reduced thrombo- studies [14–23] that have found a benefit for surveillance
sis. For graft survival (Fig. 6C), the CIs indicate that if may have been biased because of inadequate randomiza-
Qa and stenosis surveillance increased the probability of tion or historic control groups.
survival, it was by no more than 0.24 and 0.27, respectively. While planning this study, we were strongly influenced
by the landmark studies of Schwab et al [15] and Besarab
et al [16]. Both nonrandomized studies observed approx-DISCUSSION
imately fourfold reductions in access failure after imple-To our knowledge, this is the first randomized con-
menting surveillance. Thus, we were surprised to find notrolled trial that has studied the influence of blood flow
improvement in graft survival in this study’s surveillance(Qa) surveillance on graft survival, and the first to com-
groups. This raises an important question: how small apare Qa and stenosis surveillance. We found that Qa and
difference in 2-year graft survival could we have de-stenosis surveillance were not associated with improved
tected? Figure 6C shows 95% CIs for differences betweengraft survival, although thrombosis was reduced in the
surveillance groups and control group. The CIs show,stenosis group. The substantial thrombosis and PTA
for example, that we cannot exclude the possibility thatrates in this study indicate that progressive stenosis char-
the probability of graft survival in the flow group was asacterized our graft population (Table 3, Figs. 2 and 3).
much as 0.24 higher than in the control group. Thus, thisThus, our patients were well-suited for testing the hy-
study shows that if a surveillance benefit exists, it ispothesis that surveillance with intervention prolongs
modest at best and far less than in the two landmarkgraft life.
studies [15, 16]. Nevertheless, in our opinion, an improve-The results of this study underscore the need for ran-
ment in survival probability smaller than 0.24 may be largedomization with concurrent controls when testing
enough to justify surveillance. Thus, larger randomizedhypotheses [24–28]. The purpose of randomization is to
controlled trials are needed to better define whetherhelp ensure an unbiased assessment of a treatment bene-
surveillance provides a significant survival benefit.fit by selecting study groups that are equivalent in all
respects other than the treatment itself [38]. Previous In contrast to graft survival, this study supports the
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Table 4. Factors that may account for failure of surveillance to prolong graft life in this study
1. Timely intervention may reduce thrombosis rates without ultimately influencing graft survival;
2. Surveillance may provide an improvement in graft survival that is modest at best and requires a larger sample size to detect;
3. Monthly blood flow (Qa) measurements do not accurately detect progressive stenosis;
4. Quarterly stenosis measurements are not sufficiently frequent to detect progressive stenosis in many grafts;
5. Unnecessary or premature percutaneous transluminal angioplasty (PTAs) may adversely affect graft survival;
6. Aggressive clinical monitoring may provide most or all of the benefit provided by preemptive intervention;
7. The benefit of surveillance may be limited to a subset of grafts.
concept that aggressive preemptive PTA reduces throm- (N.M. Krivitski, personal communication) recommended
that measurements should ideally be in the first hour,bosis. The stenosis group, which had the highest preemp-
tive PTA rate (0.65/patient year), had the lowest throm- but he also noted that this might be impractical [12]. In
order to settle this issue, we evaluated seven consecutivebosis rate and lowest percentage of thrombosed grafts.
As the 95% CIs in Figure 6 A and B show, these differ- sessions in 51 patients [12]. We found wide hemodynamic
variation from the beginning of dialysis, indicating thatences were not quite significant. Given that we were
specifically seeking reduced thrombosis in the surveil- hemodynamic stability does not characterize the early
part of a session as is so widely believed. We concludedlance groups, one-tailed rather than two-tailed P values
could be used. This would reduce P by one half and that any restriction on timing of measurements is without
benefit [12, 13]. Thus, it is unlikely that early Qa measure-thereby yield significance (CIs would exclude zero). Ste-
nosis surveillance was potentially beneficial because, by ments would have altered our results.
Some have suggested that decrease in Qa (	Qa) is areducing the unscheduled PTA rate, it may have reduced
hospitalization and use of central venous catheters. It is more accurate predictor of thrombosis than a single Qa
value [10]. Thus, it might be argued that surveillancepossible, however, that this advantage was offset by the
stenosis group’s high rate of procedures, some of which based upon 	Qa might have been more successful. How-
ever, the assertion that 	Qa is superior was based uponmight have been unnecessary or premature (see below).
It is important to explore why surveillance did not a comparison of two separate studies, rather than a com-
parison of Qa and 	Qa within the same study [9, 10]. Theimprove graft survival in this study (Table 4). The most
obvious explanation may be that timely intervention re- apparent superiority of 	Qa is misleading because many
grafts with normal Qas thrombose before 	Qa can beduces thrombosis without ultimately influencing graft
survival. However, a number of other possibilities should measured [5, 10]. This has caused a bias in favor of 	Qa
[13]. We have used logistic regression to show that whenalso be considered.
A key factor in the flow group may be that Qa is not 	Qa is combined with single Qa in the same model, 	Qa
is not a significant predictor of thrombosis [40]. Further,accurate in detecting progressive stenosis or predicting
thrombosis [5–8, 11]. Review of monthly Qa values before combined prediction of thrombosis by either Qa 600
mL/min or 	Qa 20% has a sensitivity of only 59% withthrombosis shows most thromboses were preceded by
Qas that were well above the 600 mL/min threshold used a false positive rate of 23% [5, 11]. Thus, it is unlikely
that	Qa would have enhanced the benefit of surveillanceto refer for preemptive PTA in the flow group (Fig. 4).
This poor predictive accuracy is mainly caused by wide in this study.
In the stenosis group, quarterly stenosis measurementshemodynamic variation during dialysis, which impairs
the reproducibility of Qa measurements [12, 13]. Rapid may not have been sufficiently frequent to provide a
timely warning of progressive stenosis. For example, ap-progression of stenosis in young grafts is also probably
a factor (abstract; Atray et al, J Am Soc Nephrol 12:281A, proximately one third of our patients’ grafts thrombose
within 90 days of placement. We have recently used2001; abstract; Zaman et al, J Am Soc Nephrol 10:233A,
1999). duplex ultrasound and angiography studies to show that
early thrombosis is associated with rapid progression ofSome might argue that patients are hemodynamically
stable early in a dialysis session, so that if we had mea- stenosis at the venous anastomosis (abstract; Atray et al,
J Am Soc Nephrol 12:281A, 2001; abstract; Zaman et al,sured Qa in the first 30 minutes rather than during the
greater part of a session, we might have had greater J Am Soc Nephrol 10:233A, 1999}. Thus, stenosis measure-
ments may need to be more frequent than quarterly.accuracy in detecting stenosis. Concern that such a re-
striction is impractical led Rehman et al [39] to study The possibility that unnecessary or premature PTAs
impaired graft survival should also be considered. In thethis issue. They concluded that measurements could be
done anytime in the first 90 minutes (and often in the stenosis group, intervention was based on stenosis50%
without regard to whether stenosis was progressive. Withfirst 120 to 150 minutes) of a session. The senior scientist
of the manufacturer of the ultrasound dilution device respect to the flow group, Qa measurements frequently
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yield false positive predictions of thrombosis [5–8, 11]. should not be applied to all patients unless it is shown
to be superior to clinical monitoring.For example, hemodynamic variation during dialysis
As a final consideration, recall that in the two random-may cause a temporary but misleading decrease in Qa.
ized controlled trials that found stenosis surveillance im-Subsequent PTA of a stable stenosis might then shorten
proves survival, the investigators studied new grafts [30]graft life by stimulating neointimal hyperplasia. [41]. It
or grafts without prior procedures [32]. This suggestsis noteworthy that Dember, Holmberg, and Kaufman
that the benefit of surveillance might be restricted to a[33] have similarly found that static venous pressure has
subset of grafts. In contrast, our proportional hazardsa poor predictive accuracy that may result in many un-
model showed no evidence of an influence of graft agenecessary, invasive, and costly procedures. This under-
or prior procedures on thrombosis or survival. Thus, wescores the need to develop more accurate methods of
found no evidence that a subset of grafts benefited fromassessing risk of thrombosis so that the benefit of proce-
surveillance.dures can be assured.
Finally, a high baseline PTA rate might help explain
why the control group’s graft survival was similar to the CONCLUSION
surveillance groups. The preemptive PTA rate in the
This randomized controlled trial failed to show thatcontrol group (0.22/patient year) was two thirds the rate
Qa surveillance reduced thrombosis or prolonged graftin the flow group (0.34/patient year). By comparison,
life, whereas stenosis surveillance did reduce thrombosisthis rate is moderately higher than the baseline rate of
without prolonging graft life. This study provides many0.09/patient year by McCarley et al [20]. It is possible
insights that may assist in designing the larger (probably
that our higher rate provided most of the benefit that may
multicenter) randomized controlled trials that are needed
follow from preemptive intervention. This rate likely to further evaluate the costs and benefits of surveillance.
reflects the fact that the nephrologists in this study were We believe that until the results of such trials are avail-
members of an interventional nephrology program. able, it is not possible to make definitive evidence-based
Thus, the nephrologists and dialysis staff made clinical recommendations concerning graft surveillance.
recognition of graft problems a high priority.
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